Research programme: omega-3-fatty acid therapeutics - Matinas BioPharmaAlternative Names: MAT-8800
Latest Information Update: 19 May 2015
At a glance
- Originator Matinas BioPharma
- Class Omega 3 fatty acids
- Mechanism of Action Triglyceride modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Fatty liver